Biosimilar Monoclonal Antibody Market By Type (Adalimumab, Bevacizumab, Infliximab, Rituximab, Trastuzumab, Others), By Indication (Oncology, Autoimmune diseases, Others), By End User (Hospitals, Cancer treatment centers, Others): Global Opportunity Analysis and Industry Forecast, 2023-2032
The biosimilar monoclonal antibody market was valued for $8,727.00 million in 2022 and is estimated to reach $64,699.19 million by 2032, exhibiting a CAGR of 22.2% from 2023 to 2032. Biosimilar monoclonal antibodies are biologic treatments that closely resemble established reference monoclonal antibodies, commonly referred to as originator or innovator monoclonal antibodies. These similarities encompass aspects such as structure, function, effectiveness, safety, and quality. Monoclonal antibodies (mAbs) are large proteins produced in living cells and are designed to target specific molecules or cells in the body involved in disease processes. Biosimilar monoclonal antibodies find application in a range of therapeutic areas, including oncology, immunology, and infectious diseases. Biosimilar monoclonal antibodies are produced by different manufacturers other than the originator product but demonstrate no clinically meaningful differences from the reference product. They undergo rigorous analytical and clinical testing to establish their similarity with reference biosimilars and demonstrate safety and efficacy.
The major factors driving the growth of biosimilar monoclonal antibody market are increasing demand for biosimilar mAbs, supportive regulatory environment, and increase in patent expirations of blockbuster monoclonal antibodies. Monoclonal antibodies and similar biologic medications have emerged as essential choices for addressing a variety of persistent and intricate health conditions, including cancer, autoimmune disorders, and inflammatory issues. Rise in prevalence of these diseases, coupled with the increasing aging population, has led to a higher demand for biologics, including biosimilar mAbs. In addition, biosimilar mAbs are generally more cost-effective than their originator counterparts. As the innovative monoclonal antibodies are highly costly, healthcare providers and payers are increasingly seeking cost-saving options without compromising on therapeutic efficacy. Biosimilars offer a more affordable treatment option, which can lead to increase in adoption in both, developed and developing markets.
Furthermore, due to patent expirations and advancements in biotechnological research, manufacturers of biosimilars have had the opportunity to investigate fresh therapeutic applications for their offerings. This widens the potential applications of biosimilar mAbs. Furthermore, increase in the number of biosimilar manufacturers and their willingness to invest in R&D and production capabilities have intensified competition in the biosimilar mAbs market, which contributes to lowering prices and enhancing overall market penetration. Moreover, regulatory agencies in many countries, including the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA), have established clear guidelines for the approval of biosimilar products. These guidelines provide a transparent pathway for development, testing, and approval of biosimilar mAbs, which boosts the confidence of manufacturers entering the market.
The biosimilar monoclonal antibody market is segmented on the type, indication, end user and region. On the basis of type, the market is categorized into adalimumab, bevacizumab, infliximab, rituximab, trastuzumab, and others. On the basis of indication, the market is classified into oncology, autoimmune diseases, and others. On the basis of end user, the market is segmented into hospitals, cancer treatment centers and others. Region-wise, the market is analyzed across North America (the U.S., Canada, and Mexico), Europe (Germany, France, the UK, Italy, Spain, and rest of Europe), Asia-Pacific (Japan, China, Australia, India, South Korea, and rest of Asia-Pacific), and LAMEA (Brazil, South Africa, Saudi Arabia, and rest of LAMEA).
Major key players that operate in the global biosimilar monoclonal antibody market are Novartis AG, Pfizer Inc., Amgen Inc., Coherus BioSciences, Inc., Teva Pharmaceutical Industries Limited, Shanghai Henlius Biotech, Inc., BIOCAD, Biogen, Biocon, and Celltrion Healthcare Co., Ltd. The key players have adopted strategies such as collaboration, product launch, agreement, clinical trial approval, acquisition, and product approval to expand their product portfolio.
Key Benefits for Stakeholders
This report provides a quantitative analysis of the market segments, current trends, estimations, and dynamics of the biosimilar monoclonal antibody market analysis from 2022 to 2032 to identify the prevailing biosimilar monoclonal antibody market opportunities.
The market research is offered along with information related to key drivers, restraints, and opportunities.
Porter's five forces analysis highlights the potency of buyers and suppliers to enable stakeholders make profit-oriented business decisions and strengthen their supplier-buyer network.
In-depth analysis of the biosimilar monoclonal antibody market segmentation assists to determine the prevailing market opportunities.
Major countries in each region are mapped according to their revenue contribution to the global market.
Market player positioning facilitates benchmarking and provides a clear understanding of the present position of the market players.
The report includes the analysis of the regional as well as global biosimilar monoclonal antibody market trends, key players, market segments, application areas, and market growth strategies.
Key Market Segments
By Type
Adalimumab
Bevacizumab
Infliximab
Rituximab
Trastuzumab
Others
By Indication
Oncology
Autoimmune diseases
Others
By End User
Hospitals
Cancer treatment centers
Others
By Region
North America
U.S.
Canada
Mexico
Europe
Germany
France
UK
Italy
Spain
Rest of Europe
Asia-Pacific
Japan
China
India
Australia
South Korea
Rest of Asia-Pacific
LAMEA
Brazil
Saudi Arabia
South Africa
Rest of LAMEA
Key Market Players
Amgen Inc.
Novartis AG
Teva Pharmaceutical Industries Limited
Shanghai Henlius Biotech, Inc.
BIOCAD
Celltrion Healthcare Co., Ltd.
Biocon
Coherus BioSciences, Inc.
Pfizer Inc.
Biogen
Please Note: It will take 7-10 business days to complete the report upon order confirmation.
- CHAPTER 1: INTRODUCTION
- 1.1. Report description
- 1.2. Key market segments
- 1.3. Key benefits to the stakeholders
- 1.4. Research Methodology
- 1.4.1. Primary research
- 1.4.2. Secondary research
- 1.4.3. Analyst tools and models
- CHAPTER 2: EXECUTIVE SUMMARY
- 2.1. CXO Perspective
- CHAPTER 3: MARKET OVERVIEW
- 3.1. Market definition and scope
- 3.2. Key findings
- 3.2.1. Top impacting factors
- 3.2.2. Top investment pockets
- 3.3. Porter’s five forces analysis
- 3.3.1. High bargaining power of suppliers
- 3.3.2. High threat of new entrants
- 3.3.3. Moderate threat of substitutes
- 3.3.4. Moderate intensity of rivalry
- 3.3.5. High bargaining power of buyers
- 3.4. Market dynamics
- 3.4.1. Drivers
- 3.4.1.1. Increase in prevalence of chronic diseases
- 3.4.1.2. Rise in number of product approvals for biosimilar monoclonal antibodies
- 3.4.1.3. Expiration of patents
- 3.4.2. Restraints
- 3.4.2.1. Intellectual property and legal challenges
- 3.4.3. Opportunities
- 3.4.3.1. Growing opportunities in emerging markets
- 3.4.3.2. Increase in number of pipeline drugs
- CHAPTER 4: BIOSIMILAR MONOCLONAL ANTIBODY MARKET, BY TYPE
- 4.1. Overview
- 4.1.1. Market size and forecast
- 4.2. Adalimumab
- 4.2.1. Key market trends, growth factors and opportunities
- 4.2.2. Market size and forecast, by region
- 4.2.3. Market share analysis by country
- 4.3. Bevacizumab
- 4.3.1. Key market trends, growth factors and opportunities
- 4.3.2. Market size and forecast, by region
- 4.3.3. Market share analysis by country
- 4.4. Infliximab
- 4.4.1. Key market trends, growth factors and opportunities
- 4.4.2. Market size and forecast, by region
- 4.4.3. Market share analysis by country
- 4.5. Rituximab
- 4.5.1. Key market trends, growth factors and opportunities
- 4.5.2. Market size and forecast, by region
- 4.5.3. Market share analysis by country
- 4.6. Trastuzumab
- 4.6.1. Key market trends, growth factors and opportunities
- 4.6.2. Market size and forecast, by region
- 4.6.3. Market share analysis by country
- 4.7. Others
- 4.7.1. Key market trends, growth factors and opportunities
- 4.7.2. Market size and forecast, by region
- 4.7.3. Market share analysis by country
- CHAPTER 5: BIOSIMILAR MONOCLONAL ANTIBODY MARKET, BY INDICATION
- 5.1. Overview
- 5.1.1. Market size and forecast
- 5.2. Oncology
- 5.2.1. Key market trends, growth factors and opportunities
- 5.2.2. Market size and forecast, by region
- 5.2.3. Market share analysis by country
- 5.3. Autoimmune diseases
- 5.3.1. Key market trends, growth factors and opportunities
- 5.3.2. Market size and forecast, by region
- 5.3.3. Market share analysis by country
- 5.4. Others
- 5.4.1. Key market trends, growth factors and opportunities
- 5.4.2. Market size and forecast, by region
- 5.4.3. Market share analysis by country
- CHAPTER 6: BIOSIMILAR MONOCLONAL ANTIBODY MARKET, BY END USER
- 6.1. Overview
- 6.1.1. Market size and forecast
- 6.2. Hospitals
- 6.2.1. Key market trends, growth factors and opportunities
- 6.2.2. Market size and forecast, by region
- 6.2.3. Market share analysis by country
- 6.3. Cancer treatment centers
- 6.3.1. Key market trends, growth factors and opportunities
- 6.3.2. Market size and forecast, by region
- 6.3.3. Market share analysis by country
- 6.4. Others
- 6.4.1. Key market trends, growth factors and opportunities
- 6.4.2. Market size and forecast, by region
- 6.4.3. Market share analysis by country
- CHAPTER 7: BIOSIMILAR MONOCLONAL ANTIBODY MARKET, BY REGION
- 7.1. Overview
- 7.1.1. Market size and forecast By Region
- 7.2. North America
- 7.2.1. Key market trends, growth factors and opportunities
- 7.2.2. Market size and forecast, by Type
- 7.2.3. Market size and forecast, by Indication
- 7.2.4. Market size and forecast, by End User
- 7.2.5. Market size and forecast, by country
- 7.2.5.1. U.S.
- 7.2.5.1.1. Market size and forecast, by Type
- 7.2.5.1.2. Market size and forecast, by Indication
- 7.2.5.1.3. Market size and forecast, by End User
- 7.2.5.2. Canada
- 7.2.5.2.1. Market size and forecast, by Type
- 7.2.5.2.2. Market size and forecast, by Indication
- 7.2.5.2.3. Market size and forecast, by End User
- 7.2.5.3. Mexico
- 7.2.5.3.1. Market size and forecast, by Type
- 7.2.5.3.2. Market size and forecast, by Indication
- 7.2.5.3.3. Market size and forecast, by End User
- 7.3. Europe
- 7.3.1. Key market trends, growth factors and opportunities
- 7.3.2. Market size and forecast, by Type
- 7.3.3. Market size and forecast, by Indication
- 7.3.4. Market size and forecast, by End User
- 7.3.5. Market size and forecast, by country
- 7.3.5.1. Germany
- 7.3.5.1.1. Market size and forecast, by Type
- 7.3.5.1.2. Market size and forecast, by Indication
- 7.3.5.1.3. Market size and forecast, by End User
- 7.3.5.2. France
- 7.3.5.2.1. Market size and forecast, by Type
- 7.3.5.2.2. Market size and forecast, by Indication
- 7.3.5.2.3. Market size and forecast, by End User
- 7.3.5.3. UK
- 7.3.5.3.1. Market size and forecast, by Type
- 7.3.5.3.2. Market size and forecast, by Indication
- 7.3.5.3.3. Market size and forecast, by End User
- 7.3.5.4. Italy
- 7.3.5.4.1. Market size and forecast, by Type
- 7.3.5.4.2. Market size and forecast, by Indication
- 7.3.5.4.3. Market size and forecast, by End User
- 7.3.5.5. Spain
- 7.3.5.5.1. Market size and forecast, by Type
- 7.3.5.5.2. Market size and forecast, by Indication
- 7.3.5.5.3. Market size and forecast, by End User
- 7.3.5.6. Rest of Europe
- 7.3.5.6.1. Market size and forecast, by Type
- 7.3.5.6.2. Market size and forecast, by Indication
- 7.3.5.6.3. Market size and forecast, by End User
- 7.4. Asia-Pacific
- 7.4.1. Key market trends, growth factors and opportunities
- 7.4.2. Market size and forecast, by Type
- 7.4.3. Market size and forecast, by Indication
- 7.4.4. Market size and forecast, by End User
- 7.4.5. Market size and forecast, by country
- 7.4.5.1. Japan
- 7.4.5.1.1. Market size and forecast, by Type
- 7.4.5.1.2. Market size and forecast, by Indication
- 7.4.5.1.3. Market size and forecast, by End User
- 7.4.5.2. China
- 7.4.5.2.1. Market size and forecast, by Type
- 7.4.5.2.2. Market size and forecast, by Indication
- 7.4.5.2.3. Market size and forecast, by End User
- 7.4.5.3. India
- 7.4.5.3.1. Market size and forecast, by Type
- 7.4.5.3.2. Market size and forecast, by Indication
- 7.4.5.3.3. Market size and forecast, by End User
- 7.4.5.4. Australia
- 7.4.5.4.1. Market size and forecast, by Type
- 7.4.5.4.2. Market size and forecast, by Indication
- 7.4.5.4.3. Market size and forecast, by End User
- 7.4.5.5. South Korea
- 7.4.5.5.1. Market size and forecast, by Type
- 7.4.5.5.2. Market size and forecast, by Indication
- 7.4.5.5.3. Market size and forecast, by End User
- 7.4.5.6. Rest of Asia-Pacific
- 7.4.5.6.1. Market size and forecast, by Type
- 7.4.5.6.2. Market size and forecast, by Indication
- 7.4.5.6.3. Market size and forecast, by End User
- 7.5. LAMEA
- 7.5.1. Key market trends, growth factors and opportunities
- 7.5.2. Market size and forecast, by Type
- 7.5.3. Market size and forecast, by Indication
- 7.5.4. Market size and forecast, by End User
- 7.5.5. Market size and forecast, by country
- 7.5.5.1. Brazil
- 7.5.5.1.1. Market size and forecast, by Type
- 7.5.5.1.2. Market size and forecast, by Indication
- 7.5.5.1.3. Market size and forecast, by End User
- 7.5.5.2. Saudi Arabia
- 7.5.5.2.1. Market size and forecast, by Type
- 7.5.5.2.2. Market size and forecast, by Indication
- 7.5.5.2.3. Market size and forecast, by End User
- 7.5.5.3. South Africa
- 7.5.5.3.1. Market size and forecast, by Type
- 7.5.5.3.2. Market size and forecast, by Indication
- 7.5.5.3.3. Market size and forecast, by End User
- 7.5.5.4. Rest of LAMEA
- 7.5.5.4.1. Market size and forecast, by Type
- 7.5.5.4.2. Market size and forecast, by Indication
- 7.5.5.4.3. Market size and forecast, by End User
- CHAPTER 8: COMPETITIVE LANDSCAPE
- 8.1. Introduction
- 8.2. Top winning strategies
- 8.3. Product Mapping of Top 10 Player
- 8.4. Competitive Dashboard
- 8.5. Competitive Heatmap
- 8.6. Top player positioning, 2022
- CHAPTER 9: COMPANY PROFILES
- 9.1. Pfizer Inc.
- 9.1.1. Company overview
- 9.1.2. Key Executives
- 9.1.3. Company snapshot
- 9.1.4. Operating business segments
- 9.1.5. Product portfolio
- 9.1.6. Business performance
- 9.1.7. Key strategic moves and developments
- 9.2. Amgen Inc.
- 9.2.1. Company overview
- 9.2.2. Key Executives
- 9.2.3. Company snapshot
- 9.2.4. Operating business segments
- 9.2.5. Product portfolio
- 9.2.6. Business performance
- 9.2.7. Key strategic moves and developments
- 9.3. Novartis AG
- 9.3.1. Company overview
- 9.3.2. Key Executives
- 9.3.3. Company snapshot
- 9.3.4. Operating business segments
- 9.3.5. Product portfolio
- 9.3.6. Business performance
- 9.3.7. Key strategic moves and developments
- 9.4. Coherus BioSciences, Inc.
- 9.4.1. Company overview
- 9.4.2. Key Executives
- 9.4.3. Company snapshot
- 9.4.4. Operating business segments
- 9.4.5. Product portfolio
- 9.4.6. Business performance
- 9.4.7. Key strategic moves and developments
- 9.5. Teva Pharmaceutical Industries Limited
- 9.5.1. Company overview
- 9.5.2. Key Executives
- 9.5.3. Company snapshot
- 9.5.4. Operating business segments
- 9.5.5. Product portfolio
- 9.5.6. Business performance
- 9.5.7. Key strategic moves and developments
- 9.6. Shanghai Henlius Biotech, Inc.
- 9.6.1. Company overview
- 9.6.2. Key Executives
- 9.6.3. Company snapshot
- 9.6.4. Operating business segments
- 9.6.5. Product portfolio
- 9.6.6. Business performance
- 9.6.7. Key strategic moves and developments
- 9.7. BIOCAD
- 9.7.1. Company overview
- 9.7.2. Key Executives
- 9.7.3. Company snapshot
- 9.7.4. Operating business segments
- 9.7.5. Product portfolio
- 9.8. Biocon
- 9.8.1. Company overview
- 9.8.2. Key Executives
- 9.8.3. Company snapshot
- 9.8.4. Operating business segments
- 9.8.5. Product portfolio
- 9.8.6. Business performance
- 9.8.7. Key strategic moves and developments
- 9.9. Celltrion Healthcare Co., Ltd.
- 9.9.1. Company overview
- 9.9.2. Key Executives
- 9.9.3. Company snapshot
- 9.9.4. Operating business segments
- 9.9.5. Product portfolio
- 9.9.6. Business performance
- 9.9.7. Key strategic moves and developments
- 9.10. Biogen
- 9.10.1. Company overview
- 9.10.2. Key Executives
- 9.10.3. Company snapshot
- 9.10.4. Operating business segments
- 9.10.5. Product portfolio
- 9.10.6. Business performance
- 9.10.7. Key strategic moves and developments
- LIST OF TABLES
- TABLE 01. GLOBAL BIOSIMILAR MONOCLONAL ANTIBODY MARKET, BY TYPE, 2022-2032 ($MILLION)
- TABLE 02. BIOSIMILAR MONOCLONAL ANTIBODY MARKET FOR ADALIMUMAB, BY REGION, 2022-2032 ($MILLION)
- TABLE 03. BIOSIMILAR MONOCLONAL ANTIBODY MARKET FOR BEVACIZUMAB, BY REGION, 2022-2032 ($MILLION)
- TABLE 04. BIOSIMILAR MONOCLONAL ANTIBODY MARKET FOR INFLIXIMAB, BY REGION, 2022-2032 ($MILLION)
- TABLE 05. BIOSIMILAR MONOCLONAL ANTIBODY MARKET FOR RITUXIMAB, BY REGION, 2022-2032 ($MILLION)
- TABLE 06. BIOSIMILAR MONOCLONAL ANTIBODY MARKET FOR TRASTUZUMAB, BY REGION, 2022-2032 ($MILLION)
- TABLE 07. BIOSIMILAR MONOCLONAL ANTIBODY MARKET FOR OTHERS, BY REGION, 2022-2032 ($MILLION)
- TABLE 08. GLOBAL BIOSIMILAR MONOCLONAL ANTIBODY MARKET, BY INDICATION, 2022-2032 ($MILLION)
- TABLE 09. BIOSIMILAR MONOCLONAL ANTIBODY MARKET FOR ONCOLOGY, BY REGION, 2022-2032 ($MILLION)
- TABLE 10. BIOSIMILAR MONOCLONAL ANTIBODY MARKET FOR AUTOIMMUNE DISEASES, BY REGION, 2022-2032 ($MILLION)
- TABLE 11. BIOSIMILAR MONOCLONAL ANTIBODY MARKET FOR OTHERS, BY REGION, 2022-2032 ($MILLION)
- TABLE 12. GLOBAL BIOSIMILAR MONOCLONAL ANTIBODY MARKET, BY END USER, 2022-2032 ($MILLION)
- TABLE 13. BIOSIMILAR MONOCLONAL ANTIBODY MARKET FOR HOSPITALS, BY REGION, 2022-2032 ($MILLION)
- TABLE 14. BIOSIMILAR MONOCLONAL ANTIBODY MARKET FOR CANCER TREATMENT CENTERS, BY REGION, 2022-2032 ($MILLION)
- TABLE 15. BIOSIMILAR MONOCLONAL ANTIBODY MARKET FOR OTHERS, BY REGION, 2022-2032 ($MILLION)
- TABLE 16. BIOSIMILAR MONOCLONAL ANTIBODY MARKET, BY REGION, 2022-2032 ($MILLION)
- TABLE 17. NORTH AMERICA BIOSIMILAR MONOCLONAL ANTIBODY MARKET, BY TYPE, 2022-2032 ($MILLION)
- TABLE 18. NORTH AMERICA BIOSIMILAR MONOCLONAL ANTIBODY MARKET, BY INDICATION, 2022-2032 ($MILLION)
- TABLE 19. NORTH AMERICA BIOSIMILAR MONOCLONAL ANTIBODY MARKET, BY END USER, 2022-2032 ($MILLION)
- TABLE 20. NORTH AMERICA BIOSIMILAR MONOCLONAL ANTIBODY MARKET, BY COUNTRY, 2022-2032 ($MILLION)
- TABLE 21. U.S. BIOSIMILAR MONOCLONAL ANTIBODY MARKET, BY TYPE, 2022-2032 ($MILLION)
- TABLE 22. U.S. BIOSIMILAR MONOCLONAL ANTIBODY MARKET, BY INDICATION, 2022-2032 ($MILLION)
- TABLE 23. U.S. BIOSIMILAR MONOCLONAL ANTIBODY MARKET, BY END USER, 2022-2032 ($MILLION)
- TABLE 24. CANADA BIOSIMILAR MONOCLONAL ANTIBODY MARKET, BY TYPE, 2022-2032 ($MILLION)
- TABLE 25. CANADA BIOSIMILAR MONOCLONAL ANTIBODY MARKET, BY INDICATION, 2022-2032 ($MILLION)
- TABLE 26. CANADA BIOSIMILAR MONOCLONAL ANTIBODY MARKET, BY END USER, 2022-2032 ($MILLION)
- TABLE 27. MEXICO BIOSIMILAR MONOCLONAL ANTIBODY MARKET, BY TYPE, 2022-2032 ($MILLION)
- TABLE 28. MEXICO BIOSIMILAR MONOCLONAL ANTIBODY MARKET, BY INDICATION, 2022-2032 ($MILLION)
- TABLE 29. MEXICO BIOSIMILAR MONOCLONAL ANTIBODY MARKET, BY END USER, 2022-2032 ($MILLION)
- TABLE 30. EUROPE BIOSIMILAR MONOCLONAL ANTIBODY MARKET, BY TYPE, 2022-2032 ($MILLION)
- TABLE 31. EUROPE BIOSIMILAR MONOCLONAL ANTIBODY MARKET, BY INDICATION, 2022-2032 ($MILLION)
- TABLE 32. EUROPE BIOSIMILAR MONOCLONAL ANTIBODY MARKET, BY END USER, 2022-2032 ($MILLION)
- TABLE 33. EUROPE BIOSIMILAR MONOCLONAL ANTIBODY MARKET, BY COUNTRY, 2022-2032 ($MILLION)
- TABLE 34. GERMANY BIOSIMILAR MONOCLONAL ANTIBODY MARKET, BY TYPE, 2022-2032 ($MILLION)
- TABLE 35. GERMANY BIOSIMILAR MONOCLONAL ANTIBODY MARKET, BY INDICATION, 2022-2032 ($MILLION)
- TABLE 36. GERMANY BIOSIMILAR MONOCLONAL ANTIBODY MARKET, BY END USER, 2022-2032 ($MILLION)
- TABLE 37. FRANCE BIOSIMILAR MONOCLONAL ANTIBODY MARKET, BY TYPE, 2022-2032 ($MILLION)
- TABLE 38. FRANCE BIOSIMILAR MONOCLONAL ANTIBODY MARKET, BY INDICATION, 2022-2032 ($MILLION)
- TABLE 39. FRANCE BIOSIMILAR MONOCLONAL ANTIBODY MARKET, BY END USER, 2022-2032 ($MILLION)
- TABLE 40. UK BIOSIMILAR MONOCLONAL ANTIBODY MARKET, BY TYPE, 2022-2032 ($MILLION)
- TABLE 41. UK BIOSIMILAR MONOCLONAL ANTIBODY MARKET, BY INDICATION, 2022-2032 ($MILLION)
- TABLE 42. UK BIOSIMILAR MONOCLONAL ANTIBODY MARKET, BY END USER, 2022-2032 ($MILLION)
- TABLE 43. ITALY BIOSIMILAR MONOCLONAL ANTIBODY MARKET, BY TYPE, 2022-2032 ($MILLION)
- TABLE 44. ITALY BIOSIMILAR MONOCLONAL ANTIBODY MARKET, BY INDICATION, 2022-2032 ($MILLION)
- TABLE 45. ITALY BIOSIMILAR MONOCLONAL ANTIBODY MARKET, BY END USER, 2022-2032 ($MILLION)
- TABLE 46. SPAIN BIOSIMILAR MONOCLONAL ANTIBODY MARKET, BY TYPE, 2022-2032 ($MILLION)
- TABLE 47. SPAIN BIOSIMILAR MONOCLONAL ANTIBODY MARKET, BY INDICATION, 2022-2032 ($MILLION)
- TABLE 48. SPAIN BIOSIMILAR MONOCLONAL ANTIBODY MARKET, BY END USER, 2022-2032 ($MILLION)
- TABLE 49. REST OF EUROPE BIOSIMILAR MONOCLONAL ANTIBODY MARKET, BY TYPE, 2022-2032 ($MILLION)
- TABLE 50. REST OF EUROPE BIOSIMILAR MONOCLONAL ANTIBODY MARKET, BY INDICATION, 2022-2032 ($MILLION)
- TABLE 51. REST OF EUROPE BIOSIMILAR MONOCLONAL ANTIBODY MARKET, BY END USER, 2022-2032 ($MILLION)
- TABLE 52. ASIA-PACIFIC BIOSIMILAR MONOCLONAL ANTIBODY MARKET, BY TYPE, 2022-2032 ($MILLION)
- TABLE 53. ASIA-PACIFIC BIOSIMILAR MONOCLONAL ANTIBODY MARKET, BY INDICATION, 2022-2032 ($MILLION)
- TABLE 54. ASIA-PACIFIC BIOSIMILAR MONOCLONAL ANTIBODY MARKET, BY END USER, 2022-2032 ($MILLION)
- TABLE 55. ASIA-PACIFIC BIOSIMILAR MONOCLONAL ANTIBODY MARKET, BY COUNTRY, 2022-2032 ($MILLION)
- TABLE 56. JAPAN BIOSIMILAR MONOCLONAL ANTIBODY MARKET, BY TYPE, 2022-2032 ($MILLION)
- TABLE 57. JAPAN BIOSIMILAR MONOCLONAL ANTIBODY MARKET, BY INDICATION, 2022-2032 ($MILLION)
- TABLE 58. JAPAN BIOSIMILAR MONOCLONAL ANTIBODY MARKET, BY END USER, 2022-2032 ($MILLION)
- TABLE 59. CHINA BIOSIMILAR MONOCLONAL ANTIBODY MARKET, BY TYPE, 2022-2032 ($MILLION)
- TABLE 60. CHINA BIOSIMILAR MONOCLONAL ANTIBODY MARKET, BY INDICATION, 2022-2032 ($MILLION)
- TABLE 61. CHINA BIOSIMILAR MONOCLONAL ANTIBODY MARKET, BY END USER, 2022-2032 ($MILLION)
- TABLE 62. INDIA BIOSIMILAR MONOCLONAL ANTIBODY MARKET, BY TYPE, 2022-2032 ($MILLION)
- TABLE 63. INDIA BIOSIMILAR MONOCLONAL ANTIBODY MARKET, BY INDICATION, 2022-2032 ($MILLION)
- TABLE 64. INDIA BIOSIMILAR MONOCLONAL ANTIBODY MARKET, BY END USER, 2022-2032 ($MILLION)
- TABLE 65. AUSTRALIA BIOSIMILAR MONOCLONAL ANTIBODY MARKET, BY TYPE, 2022-2032 ($MILLION)
- TABLE 66. AUSTRALIA BIOSIMILAR MONOCLONAL ANTIBODY MARKET, BY INDICATION, 2022-2032 ($MILLION)
- TABLE 67. AUSTRALIA BIOSIMILAR MONOCLONAL ANTIBODY MARKET, BY END USER, 2022-2032 ($MILLION)
- TABLE 68. SOUTH KOREA BIOSIMILAR MONOCLONAL ANTIBODY MARKET, BY TYPE, 2022-2032 ($MILLION)
- TABLE 69. SOUTH KOREA BIOSIMILAR MONOCLONAL ANTIBODY MARKET, BY INDICATION, 2022-2032 ($MILLION)
- TABLE 70. SOUTH KOREA BIOSIMILAR MONOCLONAL ANTIBODY MARKET, BY END USER, 2022-2032 ($MILLION)
- TABLE 71. REST OF ASIA-PACIFIC BIOSIMILAR MONOCLONAL ANTIBODY MARKET, BY TYPE, 2022-2032 ($MILLION)
- TABLE 72. REST OF ASIA-PACIFIC BIOSIMILAR MONOCLONAL ANTIBODY MARKET, BY INDICATION, 2022-2032 ($MILLION)
- TABLE 73. REST OF ASIA-PACIFIC BIOSIMILAR MONOCLONAL ANTIBODY MARKET, BY END USER, 2022-2032 ($MILLION)
- TABLE 74. LAMEA BIOSIMILAR MONOCLONAL ANTIBODY MARKET, BY TYPE, 2022-2032 ($MILLION)
- TABLE 75. LAMEA BIOSIMILAR MONOCLONAL ANTIBODY MARKET, BY INDICATION, 2022-2032 ($MILLION)
- TABLE 76. LAMEA BIOSIMILAR MONOCLONAL ANTIBODY MARKET, BY END USER, 2022-2032 ($MILLION)
- TABLE 77. LAMEA BIOSIMILAR MONOCLONAL ANTIBODY MARKET, BY COUNTRY, 2022-2032 ($MILLION)
- TABLE 78. BRAZIL BIOSIMILAR MONOCLONAL ANTIBODY MARKET, BY TYPE, 2022-2032 ($MILLION)
- TABLE 79. BRAZIL BIOSIMILAR MONOCLONAL ANTIBODY MARKET, BY INDICATION, 2022-2032 ($MILLION)
- TABLE 80. BRAZIL BIOSIMILAR MONOCLONAL ANTIBODY MARKET, BY END USER, 2022-2032 ($MILLION)
- TABLE 81. SAUDI ARABIA BIOSIMILAR MONOCLONAL ANTIBODY MARKET, BY TYPE, 2022-2032 ($MILLION)
- TABLE 82. SAUDI ARABIA BIOSIMILAR MONOCLONAL ANTIBODY MARKET, BY INDICATION, 2022-2032 ($MILLION)
- TABLE 83. SAUDI ARABIA BIOSIMILAR MONOCLONAL ANTIBODY MARKET, BY END USER, 2022-2032 ($MILLION)
- TABLE 84. SOUTH AFRICA BIOSIMILAR MONOCLONAL ANTIBODY MARKET, BY TYPE, 2022-2032 ($MILLION)
- TABLE 85. SOUTH AFRICA BIOSIMILAR MONOCLONAL ANTIBODY MARKET, BY INDICATION, 2022-2032 ($MILLION)
- TABLE 86. SOUTH AFRICA BIOSIMILAR MONOCLONAL ANTIBODY MARKET, BY END USER, 2022-2032 ($MILLION)
- TABLE 87. REST OF LAMEA BIOSIMILAR MONOCLONAL ANTIBODY MARKET, BY TYPE, 2022-2032 ($MILLION)
- TABLE 88. REST OF LAMEA BIOSIMILAR MONOCLONAL ANTIBODY MARKET, BY INDICATION, 2022-2032 ($MILLION)
- TABLE 89. REST OF LAMEA BIOSIMILAR MONOCLONAL ANTIBODY MARKET, BY END USER, 2022-2032 ($MILLION)
- TABLE 90. PFIZER INC.: KEY EXECUTIVES
- TABLE 91. PFIZER INC.: COMPANY SNAPSHOT
- TABLE 92. PFIZER INC.: PRODUCT SEGMENTS
- TABLE 93. PFIZER INC.: PRODUCT PORTFOLIO
- TABLE 94. PFIZER INC.: KEY STRATERGIES
- TABLE 95. AMGEN INC.: KEY EXECUTIVES
- TABLE 96. AMGEN INC.: COMPANY SNAPSHOT
- TABLE 97. AMGEN INC.: PRODUCT SEGMENTS
- TABLE 98. AMGEN INC.: PRODUCT PORTFOLIO
- TABLE 99. AMGEN INC.: KEY STRATERGIES
- TABLE 100. NOVARTIS AG: KEY EXECUTIVES
- TABLE 101. NOVARTIS AG: COMPANY SNAPSHOT
- TABLE 102. NOVARTIS AG: PRODUCT SEGMENTS
- TABLE 103. NOVARTIS AG: PRODUCT PORTFOLIO
- TABLE 104. NOVARTIS AG: KEY STRATERGIES
- TABLE 105. COHERUS BIOSCIENCES, INC.: KEY EXECUTIVES
- TABLE 106. COHERUS BIOSCIENCES, INC.: COMPANY SNAPSHOT
- TABLE 107. COHERUS BIOSCIENCES, INC.: PRODUCT SEGMENTS
- TABLE 108. COHERUS BIOSCIENCES, INC.: PRODUCT PORTFOLIO
- TABLE 109. COHERUS BIOSCIENCES, INC.: KEY STRATERGIES
- TABLE 110. TEVA PHARMACEUTICAL INDUSTRIES LIMITED: KEY EXECUTIVES
- TABLE 111. TEVA PHARMACEUTICAL INDUSTRIES LIMITED: COMPANY SNAPSHOT
- TABLE 112. TEVA PHARMACEUTICAL INDUSTRIES LIMITED: PRODUCT SEGMENTS
- TABLE 113. TEVA PHARMACEUTICAL INDUSTRIES LIMITED: PRODUCT PORTFOLIO
- TABLE 114. TEVA PHARMACEUTICAL INDUSTRIES LIMITED: KEY STRATERGIES
- TABLE 115. SHANGHAI HENLIUS BIOTECH, INC.: KEY EXECUTIVES
- TABLE 116. SHANGHAI HENLIUS BIOTECH, INC.: COMPANY SNAPSHOT
- TABLE 117. SHANGHAI HENLIUS BIOTECH, INC.: PRODUCT SEGMENTS
- TABLE 118. SHANGHAI HENLIUS BIOTECH, INC.: PRODUCT PORTFOLIO
- TABLE 119. SHANGHAI HENLIUS BIOTECH, INC.: KEY STRATERGIES
- TABLE 120. BIOCAD: KEY EXECUTIVES
- TABLE 121. BIOCAD: COMPANY SNAPSHOT
- TABLE 122. BIOCAD: PRODUCT SEGMENTS
- TABLE 123. BIOCAD: PRODUCT PORTFOLIO
- TABLE 124. BIOCON: KEY EXECUTIVES
- TABLE 125. BIOCON: COMPANY SNAPSHOT
- TABLE 126. BIOCON: PRODUCT SEGMENTS
- TABLE 127. BIOCON: PRODUCT PORTFOLIO
- TABLE 128. BIOCON: KEY STRATERGIES
- TABLE 129. CELLTRION HEALTHCARE CO., LTD.: KEY EXECUTIVES
- TABLE 130. CELLTRION HEALTHCARE CO., LTD.: COMPANY SNAPSHOT
- TABLE 131. CELLTRION HEALTHCARE CO., LTD.: PRODUCT SEGMENTS
- TABLE 132. CELLTRION HEALTHCARE CO., LTD.: PRODUCT PORTFOLIO
- TABLE 133. CELLTRION HEALTHCARE CO., LTD.: KEY STRATERGIES
- TABLE 134. BIOGEN: KEY EXECUTIVES
- TABLE 135. BIOGEN: COMPANY SNAPSHOT
- TABLE 136. BIOGEN: PRODUCT SEGMENTS
- TABLE 137. BIOGEN: PRODUCT PORTFOLIO
- TABLE 138. BIOGEN: KEY STRATERGIES
- LIST OF FIGURES
- FIGURE 01. BIOSIMILAR MONOCLONAL ANTIBODY MARKET, 2022-2032
- FIGURE 02. SEGMENTATION OF BIOSIMILAR MONOCLONAL ANTIBODY MARKET,2022-2032
- FIGURE 03. TOP INVESTMENT POCKETS IN BIOSIMILAR MONOCLONAL ANTIBODY MARKET (2023-2032)
- FIGURE 04. HIGH BARGAINING POWER OF SUPPLIERS
- FIGURE 05. HIGH THREAT OF NEW ENTRANTS
- FIGURE 06. MODERATE THREAT OF SUBSTITUTES
- FIGURE 07. MODERATE INTENSITY OF RIVALRY
- FIGURE 08. HIGH BARGAINING POWER OF BUYERS
- FIGURE 09. GLOBAL BIOSIMILAR MONOCLONAL ANTIBODY MARKET:DRIVERS, RESTRAINTS AND OPPORTUNITIES
- FIGURE 10. BIOSIMILAR MONOCLONAL ANTIBODY MARKET, BY TYPE, 2022 AND 2032(%)
- FIGURE 11. COMPARATIVE SHARE ANALYSIS OF BIOSIMILAR MONOCLONAL ANTIBODY MARKET FOR ADALIMUMAB, BY COUNTRY 2022 AND 2032(%)
- FIGURE 12. COMPARATIVE SHARE ANALYSIS OF BIOSIMILAR MONOCLONAL ANTIBODY MARKET FOR BEVACIZUMAB, BY COUNTRY 2022 AND 2032(%)
- FIGURE 13. COMPARATIVE SHARE ANALYSIS OF BIOSIMILAR MONOCLONAL ANTIBODY MARKET FOR INFLIXIMAB, BY COUNTRY 2022 AND 2032(%)
- FIGURE 14. COMPARATIVE SHARE ANALYSIS OF BIOSIMILAR MONOCLONAL ANTIBODY MARKET FOR RITUXIMAB, BY COUNTRY 2022 AND 2032(%)
- FIGURE 15. COMPARATIVE SHARE ANALYSIS OF BIOSIMILAR MONOCLONAL ANTIBODY MARKET FOR TRASTUZUMAB, BY COUNTRY 2022 AND 2032(%)
- FIGURE 16. COMPARATIVE SHARE ANALYSIS OF BIOSIMILAR MONOCLONAL ANTIBODY MARKET FOR OTHERS, BY COUNTRY 2022 AND 2032(%)
- FIGURE 17. BIOSIMILAR MONOCLONAL ANTIBODY MARKET, BY INDICATION, 2022 AND 2032(%)
- FIGURE 18. COMPARATIVE SHARE ANALYSIS OF BIOSIMILAR MONOCLONAL ANTIBODY MARKET FOR ONCOLOGY, BY COUNTRY 2022 AND 2032(%)
- FIGURE 19. COMPARATIVE SHARE ANALYSIS OF BIOSIMILAR MONOCLONAL ANTIBODY MARKET FOR AUTOIMMUNE DISEASES, BY COUNTRY 2022 AND 2032(%)
- FIGURE 20. COMPARATIVE SHARE ANALYSIS OF BIOSIMILAR MONOCLONAL ANTIBODY MARKET FOR OTHERS, BY COUNTRY 2022 AND 2032(%)
- FIGURE 21. BIOSIMILAR MONOCLONAL ANTIBODY MARKET, BY END USER, 2022 AND 2032(%)
- FIGURE 22. COMPARATIVE SHARE ANALYSIS OF BIOSIMILAR MONOCLONAL ANTIBODY MARKET FOR HOSPITALS, BY COUNTRY 2022 AND 2032(%)
- FIGURE 23. COMPARATIVE SHARE ANALYSIS OF BIOSIMILAR MONOCLONAL ANTIBODY MARKET FOR CANCER TREATMENT CENTERS, BY COUNTRY 2022 AND 2032(%)
- FIGURE 24. COMPARATIVE SHARE ANALYSIS OF BIOSIMILAR MONOCLONAL ANTIBODY MARKET FOR OTHERS, BY COUNTRY 2022 AND 2032(%)
- FIGURE 25. BIOSIMILAR MONOCLONAL ANTIBODY MARKET BY REGION, 2022 AND 2032(%)
- FIGURE 26. U.S. BIOSIMILAR MONOCLONAL ANTIBODY MARKET, 2022-2032 ($MILLION)
- FIGURE 27. CANADA BIOSIMILAR MONOCLONAL ANTIBODY MARKET, 2022-2032 ($MILLION)
- FIGURE 28. MEXICO BIOSIMILAR MONOCLONAL ANTIBODY MARKET, 2022-2032 ($MILLION)
- FIGURE 29. GERMANY BIOSIMILAR MONOCLONAL ANTIBODY MARKET, 2022-2032 ($MILLION)
- FIGURE 30. FRANCE BIOSIMILAR MONOCLONAL ANTIBODY MARKET, 2022-2032 ($MILLION)
- FIGURE 31. UK BIOSIMILAR MONOCLONAL ANTIBODY MARKET, 2022-2032 ($MILLION)
- FIGURE 32. ITALY BIOSIMILAR MONOCLONAL ANTIBODY MARKET, 2022-2032 ($MILLION)
- FIGURE 33. SPAIN BIOSIMILAR MONOCLONAL ANTIBODY MARKET, 2022-2032 ($MILLION)
- FIGURE 34. REST OF EUROPE BIOSIMILAR MONOCLONAL ANTIBODY MARKET, 2022-2032 ($MILLION)
- FIGURE 35. JAPAN BIOSIMILAR MONOCLONAL ANTIBODY MARKET, 2022-2032 ($MILLION)
- FIGURE 36. CHINA BIOSIMILAR MONOCLONAL ANTIBODY MARKET, 2022-2032 ($MILLION)
- FIGURE 37. INDIA BIOSIMILAR MONOCLONAL ANTIBODY MARKET, 2022-2032 ($MILLION)
- FIGURE 38. AUSTRALIA BIOSIMILAR MONOCLONAL ANTIBODY MARKET, 2022-2032 ($MILLION)
- FIGURE 39. SOUTH KOREA BIOSIMILAR MONOCLONAL ANTIBODY MARKET, 2022-2032 ($MILLION)
- FIGURE 40. REST OF ASIA-PACIFIC BIOSIMILAR MONOCLONAL ANTIBODY MARKET, 2022-2032 ($MILLION)
- FIGURE 41. BRAZIL BIOSIMILAR MONOCLONAL ANTIBODY MARKET, 2022-2032 ($MILLION)
- FIGURE 42. SAUDI ARABIA BIOSIMILAR MONOCLONAL ANTIBODY MARKET, 2022-2032 ($MILLION)
- FIGURE 43. SOUTH AFRICA BIOSIMILAR MONOCLONAL ANTIBODY MARKET, 2022-2032 ($MILLION)
- FIGURE 44. REST OF LAMEA BIOSIMILAR MONOCLONAL ANTIBODY MARKET, 2022-2032 ($MILLION)
- FIGURE 45. TOP WINNING STRATEGIES, BY YEAR (2020-2023)
- FIGURE 46. TOP WINNING STRATEGIES, BY DEVELOPMENT (2020-2023)
- FIGURE 47. TOP WINNING STRATEGIES, BY COMPANY (2020-2023)
- FIGURE 48. PRODUCT MAPPING OF TOP 10 PLAYERS
- FIGURE 49. COMPETITIVE DASHBOARD
- FIGURE 50. COMPETITIVE HEATMAP: BIOSIMILAR MONOCLONAL ANTIBODY MARKET
- FIGURE 51. TOP PLAYER POSITIONING, 2022
- FIGURE 52. PFIZER INC.: NET REVENUE, 2020-2022 ($MILLION)
- FIGURE 53. PFIZER INC.: REVENUE SHARE BY SEGMENT, 2022 (%)
- FIGURE 54. PFIZER INC.: REVENUE SHARE BY REGION, 2022 (%)
- FIGURE 55. AMGEN INC.: NET REVENUE, 2020-2022 ($MILLION)
- FIGURE 56. AMGEN INC.: REVENUE SHARE BY REGION, 2022 (%)
- FIGURE 57. AMGEN INC.: REVENUE SHARE BY SEGMENT, 2022 (%)
- FIGURE 58. NOVARTIS AG: NET SALES, 2020-2022 ($MILLION)
- FIGURE 59. NOVARTIS AG: REVENUE SHARE BY SEGMENT, 2022 (%)
- FIGURE 60. NOVARTIS AG: REVENUE SHARE BY REGION, 2022 (%)
- FIGURE 61. COHERUS BIOSCIENCES, INC.: NET REVENUE, 2020-2022 ($MILLION)
- FIGURE 62. TEVA PHARMACEUTICAL INDUSTRIES LIMITED: NET REVENUE, 2020-2022 ($MILLION)
- FIGURE 63. TEVA PHARMACEUTICAL INDUSTRIES LIMITED: REVENUE SHARE BY SEGMENT, 2022 (%)
- FIGURE 64. SHANGHAI HENLIUS BIOTECH, INC.: NET REVENUE, 2020-2022 ($MILLION)
- FIGURE 65. SHANGHAI HENLIUS BIOTECH, INC.: REVENUE SHARE BY REGION, 2022 (%)
- FIGURE 66. BIOCON: NET REVENUE, 2020-2022 ($MILLION)
- FIGURE 67. BIOCON: REVENUE SHARE BY REGION, 2022 (%)
- FIGURE 68. CELLTRION HEALTHCARE CO., LTD.: NET SALES, 2020-2022 ($MILLION)
- FIGURE 69. BIOGEN: NET REVENUE, 2020-2022 ($MILLION)
- FIGURE 70. BIOGEN: REVENUE SHARE BY REGION, 2022 (%)
Research Assistance
Download our eBook: How to Succeed Using Market Research
Learn how to effectively navigate the market research process to help guide your organization on the journey to success.
Download eBook